Postmarket Cybersecurity Monitoring Guide for MedTech

Ensure FDA compliance with our guide to postmarket cybersecurity monitoring for medical devices. Master vulnerability intake, risk assessments, and disclosure.

This guide is written for medical device manufacturers navigating postmarket cybersecurity monitoring. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist.

Introduction to Postmarket Cybersecurity Monitoring

Introduction to Postmarket Cybersecurity Monitoring is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

The Shift from Premarket to Continuous Security

The Shift from Premarket to Continuous Security. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

FDA Statutory Authority: Section 524B requirements

FDA Statutory Authority: Section 524B requirements. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Core Components of a Compliant Monitoring Program

Core Components of a Compliant Monitoring Program is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Vulnerability Intake and Surveillance Systems

Vulnerability Intake and Surveillance Systems. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Coordinated Vulnerability Disclosure (CVD) Processes

Coordinated Vulnerability Disclosure (CVD) Processes. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

SBOM Maintenance and Ongoing Component Tracking

SBOM Maintenance and Ongoing Component Tracking. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

The Postmarket Risk Management Framework (TIR97/ISO 14971)

The Postmarket Risk Management Framework (TIR97/ISO 14971) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Evaluating Patient Safety Impacts of New Vulnerabilities

Evaluating Patient Safety Impacts of New Vulnerabilities. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Applying CVSS in a Clinical Context

Applying CVSS in a Clinical Context. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Determining Uncontrolled vs. Controlled Risk

Determining Uncontrolled vs. Controlled Risk. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Vulnerability Identification and Remediation Cycles

Vulnerability Identification and Remediation Cycles is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

Proactive Monitoring vs. Reactive Patching

Proactive Monitoring vs. Reactive Patching. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Timelines for Remediation: The 30/60 Day Rule Guidance

Timelines for Remediation: The 30/60 Day Rule Guidance. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Deploying Updates and Patches in the Field

Deploying Updates and Patches in the Field. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Integrating Monitoring with the Quality Management System (QMS)

Integrating Monitoring with the Quality Management System (QMS) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

CAPA and Postmarket Surveillance Alignment

CAPA and Postmarket Surveillance Alignment. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Documentation Requirements for FDA Inspections

Documentation Requirements for FDA Inspections. Make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread.

Challenges in Postmarket Monitoring for Legacy Devices

Challenges in Postmarket Monitoring for Legacy Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 250+ device submissions.

How Blue Goat Cyber Approaches postmarket cybersecurity monitoring

We treat postmarket cybersecurity monitoring as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 250+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end:

• Scoping against your device profile. We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform.
• Standards mapping in writing. Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess.
• Evidence generated inside your QMS. Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit.
• Independent testing where it counts. Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices.
• Deficiency-ready posture. We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle.
• Postmarket handoff, not abandonment. Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance.

If you want that treatment applied to your postmarket cybersecurity monitoring package, our FDA Premarket Cybersecurity Services and FDA Cybersecurity Deficiency Response engagements are the two most common entry points.

Frequently asked questions

What are the FDA requirements for postmarket cybersecurity monitoring?

Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

How often should medical device manufacturers scan for vulnerabilities?

Short answer: It depends on the device classification, intended use, and connectivity profile. But the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

What is the difference between premarket and postmarket cybersecurity?

Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Do I need a Coordinated Vulnerability Disclosure (CVD) policy for the FDA?

Short answer: Yes. Under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

How does SBOM play a role in postmarket monitoring?

Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

What is the timeline for reporting a postmarket cyber vulnerability to the FDA?

Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using.

Where this fits in the cluster

This page sits downstream of our pillar resources on postmarket cybersecurity monitoring. If you arrived here from a different starting point, these are the most useful adjacent pages:

• FDA Postmarket Cybersecurity Services
• The Postmarket Cybersecurity Readiness Plan
• Legacy Medical Device Cybersecurity

Related from Blue Goat Cyber

• FDA-Compliant SBOM Services
• Medical Device Penetration Testing
• The SPDF Playbook for FDA-Ready Medical Devices
• FDA Cybersecurity Deficiency Response

Sources & primary references

• Postmarket Management of Cybersecurity in Medical Devices. FDA
• Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions. FDA
• AAMI TIR97:2019 - Principles for medical device security, Postmarket risk management for device manufacturers. AAMI
• National Vulnerability Database (CVE/CVSS). NIST/NVD

Talk to a regulatory cybersecurity team

If you are working through postmarket cybersecurity monitoring and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. Book a discovery session and we will walk your evidence with you.